Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen reports developments as a clinical-stage biotechnology company developing Wnt-based targeted therapeutics for sight-threatening ophthalmic diseases. Company updates center on its ophthalmology pipeline, including SZN-8141 and SZN-8143 in retinal diseases, antibody-engineering work, financial results, collaboration and license revenue, and research milestones tied to Boehringer Ingelheim.
Recurring announcements also cover healthcare investor conference presentations, Nasdaq inducement equity grants under the 2025 Equity Inducement Plan, and corporate governance or leadership matters that affect the company's public-company reporting profile.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Surrozen, Inc. (Nasdaq: SRZN), a biotech firm focusing on Wnt pathway therapeutics, appointed Eric Bjerkholt to its Board of Directors. Bjerkholt, who has extensive experience in biotechnology, is currently the CFO of Chinook Therapeutics and previously served as CFO of Aimmune Therapeutics, leading its $2.6 billion acquisition by Nestlé Health Science. Surrozen's Board now consists of nine members with diverse expertise in the field. CEO Craig Parker expressed confidence in Bjerkholt's insights and strategic acumen, especially as the company aims to develop technologies addressing significant medical needs.
Surrozen, Inc. (SRZN) announced key developments in its clinical pipeline, enrolling the first patient in the Phase 1a trial of SZN-043 for chronic liver disease, with data expected by the end of 2023. The company plans to initiate a Phase 1b trial for severe alcoholic hepatitis in 2024, anticipating proof-of-concept data in the latter half of 2024. SZN-1326's Phase 1a trial in healthy volunteers is set to resume by mid-2023, with potential ulcerative colitis data expected in 2024. Surrozen's restructuring initiatives have extended its cash runway into late 2024. The company's financial position includes approximately $75.8 million in cash, with R&D expenses reduced by 15% in 2023.